Temporal trends in diagnostic work-up, treatment, and mortality in locally advanced prostate cancer in 2016–2024: nationwide, population-based study in Sweden
DOI:
https://doi.org/10.2340/ao.v65.45593Abstract
Background and purpose: We aimed to describe temporal changes in diagnostic work-up, treatment, and prostate cancer (PCa) mortality in locally advanced PCa in 2016–2024 in Sweden.
Patient/material and methods: Men registered in the National Prostate Cancer Register of Sweden in 2016–2024 with locally advanced PCa; clinical T stage 3–4, no distant metastases, and prostate-specific antigen < 100 ng/ml were included. We computed the proportion of use of prostate magnetic resonance imaging (MRI) before biopsy, radical prostatectomy, radical radiotherapy, androgen deprivation therapy, and abiraterone, and described the trend in PCa mortality across three calendar periods.
Results: During the 9-year study period 7,484 men with locally advanced PCa were identified. Use of MRI before biopsy increased from 3% in 2016 to 73% in 2024. Concomitantly, radical treatment increased from 35% to 48%, entirely due to increased use of radiotherapy. Abiraterone was not used before 2022 but 31% received this treatment in 2024. The 3-year PCa mortality decreased from 8% (95% confidence interval [CI]: 7–9) in 2016–2018 to 6% (95% CI: 4–8) in 2022–2024.
Interpretation: In this nationwide, population-based study of men with locally advanced PCa, the use of MRI before biopsy, radical radiotherapy, and treatment with abiraterone increased over time. These changes coincided with a modest decrease in 3-year PCa mortality.
Downloads
References
Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815–22.
https://doi.org/10.1016/S0140-6736(16)32401-1 DOI: https://doi.org/10.1016/S0140-6736(16)32401-1
Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767–77.
https://doi.org/10.1056/NEJMoa1801993 DOI: https://doi.org/10.1056/NEJMoa1801993
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;396(10255):1208–16.
https://doi.org/10.1016/S0140-6736(20)30314-7 DOI: https://doi.org/10.1016/S0140-6736(20)30314-7
Freedland SJ, Nair S, Lin X, Karsh L, Pieczonka C, Potluri R, et al. A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients. World J Urol. 2023;41(12):3535–42.
https://doi.org/10.1007/s00345-023-04680-w DOI: https://doi.org/10.1007/s00345-023-04680-w
Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301–8.
https://doi.org/10.1016/S0140-6736(08)61815-2 DOI: https://doi.org/10.1016/S0140-6736(08)61815-2
Fosså SD, Wiklund F, Klepp O, Angelsen A, Solberg A, Damber JE, et al. Ten- and 15-yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of the Scandinavian Prostate Cancer Group-7. Eur Urol. 2016;70(4):684–91.
https://doi.org/10.1016/j.eururo.2016.03.021 DOI: https://doi.org/10.1016/j.eururo.2016.03.021
Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol. 2015;33:2143–50. DOI: https://doi.org/10.1200/JCO.2014.57.7510
Sargos P, Mottet N, Bellera C, Richaud P. Long-term androgen deprivation, with or without radiotherapy, in locally-advanced prostate cancer: updated results from a phase III randomised trial. BJU Int. 2019.
https://doi.org/10.1111/bju.14768 DOI: https://doi.org/10.1111/bju.14768
Demogeot N, Sargos P, Salleron J, Guérif S, de Crevoisier R, Calais G, et al. Short-term androgen deprivation therapy and high-dose radiotherapy in intermediate- and high-risk localized prostate cancer: results from the GETUG 14 randomized phase 3 trial. Eur Urol. 2025;88(5):510–8.
https://doi.org/10.1016/j.eururo.2025.07.019 DOI: https://doi.org/10.1016/j.eururo.2025.07.019
EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2025. Arnhem, The Netherlands: EAU Guidelines Office; 2025.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. Version 4.2023. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2023.
Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management. J Urol. 2022;208(2):245–53.
https://doi.org/10.1097/JU.0000000000002757 DOI: https://doi.org/10.1097/JU.0000000000002757
Bratt O, Carlsson S, Fransson P, Thellenberg Karlsson C, Stranne J, Kindblom J, et al. The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. 2022;56(4):265–73.
https://doi.org/10.1080/21681805.2022.2094462 DOI: https://doi.org/10.1080/21681805.2022.2094462
Stranne J. 2023/2024 update of the national prostate cancer guidelines in Sweden. Scand J Urol. 2024;59:210–1.
https://doi.org/10.2340/sju.v59.42656 DOI: https://doi.org/10.2340/sju.v59.42656
Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447–60.
https://doi.org/10.1016/S0140-6736(21)02437-5 DOI: https://doi.org/10.1016/S0140-6736(21)02437-5
Orrason AW, Westerberg M, Garmo H, Lissbrant IF, Robinson D, Stattin P. Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population-based study in Sweden. BJU Int. 2020;126(1):142–51.
https://doi.org/10.1111/bju.15077 DOI: https://doi.org/10.1111/bju.15077
Tomic K, Sandin F, Wigertz A, Robinson D, Lambe M, Stattin P. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51(1):101–11.
https://doi.org/10.1016/j.ejca.2014.10.025 DOI: https://doi.org/10.1016/j.ejca.2014.10.025
Bratt O, Butt ST, Carlsson C, Jelf-Eneqvist L, Gunnarsson O, Ihre A, et al. Swedish regional population-based organised prostate cancer testing: why, what and how? Scand J Urol. 2025;60:97–104.
https://doi.org/10.2340/sju.v60.43809 DOI: https://doi.org/10.2340/sju.v60.43809
Stattin P. How to improve cancer care by use of guidelines and quality registers. Scand J Urol. 2024;59:190–2.
https://doi.org/10.2340/sju.v59.42272 DOI: https://doi.org/10.2340/sju.v59.42272
Westerberg M, Holm L, Garmo H, Stattin P, Gedeborg R. Cohort profile update: the National Prostate Cancer Register of Sweden and PCBase. Int J Epidemiol. 2025;54(5):dyaf172.
https://doi.org/10.1093/ije/dyaf172 DOI: https://doi.org/10.1093/ije/dyaf172
Westerberg M, Ahlberg M, Orrason AW, Gedeborg R. Assessment of variability in life expectancy in older men by use of new comorbidity indices: a nationwide population-based study. Scand J Urol. 2024;59:207–9.
https://doi.org/10.2340/sju.v59.42504 DOI: https://doi.org/10.2340/sju.v59.42504
Westerberg M, Irenaeus S, Garmo H, Stattin P, Gedeborg R. Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: nationwide, population-based register study. PLoS One. 2024;19(1):e0296804.
https://doi.org/10.1371/journal.pone.0296804 DOI: https://doi.org/10.1371/journal.pone.0296804
Gedeborg R, Sund M, Lambe M, Plym A, Fredriksson I, Syrjä J, et al. An aggregated comorbidity measure based on history of filled drug prescriptions: development and evaluation in two separate cohorts. Epidemiology. 2021;32(4):607–15.
https://doi.org/10.1097/EDE.0000000000001358 DOI: https://doi.org/10.1097/EDE.0000000000001358
Van Hemelrijck M, Ventimiglia E, Robinson D, Gedeborg R, Holmberg L, Stattin, P, et al. Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males. BMC Med Inform Decis Mak. 2022;22(1):35.
https://doi.org/10.1186/s12911-022-01766-0 DOI: https://doi.org/10.1186/s12911-022-01766-0
Orrason AW, Scilipoti P, Garmo H, Gedeborg R, Styrke J, Westerberg M. Improved adherence to prostate cancer guidelines concomitant with public reporting: nationwide population-based study. Scand J Urol. 2025;60:50–8.
https://doi.org/10.2340/sju.v60.43107 DOI: https://doi.org/10.2340/sju.v60.43107
Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385–95.
https://doi.org/10.1016/S0140-6736(19)31131-6 DOI: https://doi.org/10.1016/S0140-6736(19)31131-6
Fransson P, Nilsson P, Gunnlaugsson A, Beckman L, Tavelin B, Norman D, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol. 2021;22(2):235–45.
https://doi.org/10.1016/S1470-2045(20)30581-7 DOI: https://doi.org/10.1016/S1470-2045(20)30581-7
Stranne J, Brasso K, Brennhovd B, Johansson E, Jäderling F, Kouri M, et al. SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. Scand J Urol. 2018;52(5–6):313–20. DOI: https://doi.org/10.1080/21681805.2018.1520295
Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, et al. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncol. 2023;24(5):443–56.
https://doi.org/10.1016/S1470-2045(23)00148-1 DOI: https://doi.org/10.1016/S1470-2045(23)00148-1
Kvåle R, Ursin G, Ekanger C, Møller B. Considerable decline in prostate cancer mortality in Nordic countries after 2000. Acta Oncol. 2025;64:114–9.
https://doi.org/10.2340/1651-226X.2025.41334 DOI: https://doi.org/10.2340/1651-226X.2025.41334
Albers P, Miandashti N, Broomfield S, Kinnaird A. Does the digital rectal exam still provide value in the age of MRI? Can Urol Assoc J. 2025;19(10):357–60.
https://doi.org/10.5489/cuaj.9164 DOI: https://doi.org/10.5489/cuaj.9164
Desai MM, Cacciamani GE, Gill K, Zhang J, Liu L, Abreu A, et al. Trends in incidence of metastatic prostate cancer in the US. JAMA Netw Open. 2022;5(3):e222246.
https://doi.org/10.1001/jamanetworkopen.2022.2246 DOI: https://doi.org/10.1001/jamanetworkopen.2022.2246
Kleiburg F, Dirix P, Fonteyne V, Bral S, De Troyer B, Sautois B, et al. Stage migration on prostate-specific membrane antigen positron emission tomography/computed tomography in comparison to conventional imaging in patients with high-risk prostate cancer referred for radiation therapy: results from the phase 2/3 THUNDER trial. Eur Urol Oncol. 2025;8(5):1333–9.
https://doi.org/10.1016/j.euo.2025.08.005 DOI: https://doi.org/10.1016/j.euo.2025.08.005
Additional Files
Published
How to Cite
License
Copyright (c) 2026 Armando Galdieri, Hans Garmo , Rolf Gedeborg , Mats Ahlberg, Orrason Andri Wilberg, Eugenio Ventimiglia, Pär Stattin, Marcus Westerberg
This work is licensed under a Creative Commons Attribution 4.0 International License.
